Home Other Building Blocks OLPRINONE HYDROCHLORIDE

OLPRINONE HYDROCHLORIDE

CAS No.:
119615-63-3
Catalog Number:
AG008TIP
Molecular Formula:
C14H11ClN4O
Molecular Weight:
286.7163
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%(HPLC)
In Stock USA
United States
$110
- +
10mg
98%(HPLC)
In Stock USA
United States
$187
- +
25mg
98%(HPLC)
In Stock USA
United States
$351
- +
50mg
98%(HPLC)
In Stock USA
United States
$668
- +
Product Description
Catalog Number:
AG008TIP
Chemical Name:
OLPRINONE HYDROCHLORIDE
CAS Number:
119615-63-3
Molecular Formula:
C14H11ClN4O
Molecular Weight:
286.7163
MDL Number:
MFCD00946577
IUPAC Name:
5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile;hydrochloride
InChI:
InChI=1S/C14H10N4O.ClH/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10;/h2-6,8H,1H3,(H,17,19);1H
InChI Key:
PWTBMBAQRAOAFF-UHFFFAOYSA-N
SMILES:
N#Cc1cc(c([nH]c1=O)C)c1ccc2n(c1)ccn2.Cl
UNII:
F18B658J56
Properties
Complexity:
525  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
286.062g/mol
Formal Charge:
0
Heavy Atom Count:
20  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
286.719g/mol
Monoisotopic Mass:
286.062g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
70.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury. Advances in experimental medicine and biology 20130101
Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway. American journal of physiology. Lung cellular and molecular physiology 20120701
Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury. Pulmonary pharmacology & therapeutics 20120601
[Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting]. Masui. The Japanese journal of anesthesiology 20120601
Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure. Journal of cardiology 20120501
Controlled reperfusion. General thoracic and cardiovascular surgery 20120201
Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor. General thoracic and cardiovascular surgery 20120201
[Anesthetic management of a patient with pulmonary hypertension due to a large anterior mediastinal tumor anticipated by preoperative computed tomography]. Masui. The Japanese journal of anesthesiology 20120201
Neuroprotective effects of olprinone after cerebral ischemia/reperfusion injury in rats. Neuroscience letters 20111003
[Protection from pulmonary apoptosis: a new therapeutic choice for septic acute lung injury]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20111001
Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. Pharmacological research 20110701
Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs. European journal of anaesthesiology 20110701
Effect of olprinone, a phosphodiesterase III inhibitor, on balance of cerebral oxygen supply and demand during cardiopulmonary bypass. Journal of cardiovascular pharmacology 20110501
Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts. Journal of cardiovascular pharmacology and therapeutics 20110301
Olprinone, a PDE3 inhibitor, modulates the inflammation associated with myocardial ischemia-reperfusion injury in rats. European journal of pharmacology 20110115
Determination of olprinone in human plasma utilizing liquid chromatography tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis 20110105
Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20110101
Transient cardiac arrest in patient with left ventricular noncompaction (spongiform cardiomyopathy). Anesthesia progress 20110101
Olprinone attenuates the development of ischemia/reperfusion injury of the gut. Intensive care medicine 20100701
Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemia-reperfusion injury in rats. Shock (Augusta, Ga.) 20100401
Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery. Journal of anesthesia 20100401
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction. Annals of surgery 20100401
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia. Anesthesia and analgesia 20100301
Differential vasodilation response to olprinone in rabbit renal and common carotid arteries. Journal of anesthesia 20100201
Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice. PloS one 20100101
Local application of olprinone for promotion of peripheral nerve regeneration. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20091101
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. Cardiovascular drugs and therapy 20090801
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction. Annals of surgery 20090501
The phosphodiesterase III inhibitor olprinone inhibits hippocampal glutamate release via a cGMP/PKG pathway. Neuroscience letters 20081226
[The effect of PDEIII inhibitors and colforsin daropate on hypoxic pulmonary vasoconstriction in rabbit lungs]. Masui. The Japanese journal of anesthesiology 20081101
[Anesthetic management of coronary artery bypass grafting for unstable angina pectoris in a patient undergoing home oxygen therapy]. Masui. The Japanese journal of anesthesiology 20080401
Clinically relevant concentrations of olprinone reverse attenuating effect of propofol on isoproterenol-induced cyclic adenosine monophosphate accumulation in cardiomyocytes. Hiroshima journal of medical sciences 20080301
Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulmonary pharmacology & therapeutics 20080101
Olprinone decreases elevated concentrations of cytokine-induced neutrophil chemoattractant-1 in septic rats. Journal of anesthesia 20080101
Effects of olprinone on neuromuscular blockade caused by vecuronium. Fukushima journal of medical science 20071201
[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects]. Nihon rinsho. Japanese journal of clinical medicine 20070528
[How to use PDE III inhibitors]. Nihon rinsho. Japanese journal of clinical medicine 20070528
Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure. International journal of urology : official journal of the Japanese Urological Association 20070301
Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs. Pulmonary pharmacology & therapeutics 20070101
Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. Journal of anesthesia 20070101
Effects of olprinone on myocardial ischemia-reperfusion injury in dogs. The Journal of veterinary medical science 20060801
Effects of dopamine and olprinone on ventricular energetics in sevoflurane-induced acute left ventricular depression in dogs. Journal of cardiothoracic and vascular anesthesia 20060601
The enhancement of cellular cAMP with olprinone protects autotransplanted rat kidney against cold ischemia-reperfusion injury. Transplantation proceedings 20060601
[Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting]. Masui. The Japanese journal of anesthesiology 20060201
The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation. Current vascular pharmacology 20060101
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery. European journal of pharmacology 20051228
Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries. Anesthesia and analgesia 20051001
Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock (Augusta, Ga.) 20050901
[Successful anesthetic management of three patients with cardiac dysfunction for non-cardiac surgery using olprinone hydrochloride]. Masui. The Japanese journal of anesthesiology 20050701
[Anesthetic management for an infant with tetralogy of fallot with absent pulmonary valve]. Masui. The Japanese journal of anesthesiology 20050201
Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia. Journal of anesthesia 20050101
The cerebrovascular dilatation effects of olprinone, a phosphodiesterase III inhibitor, in comparison with acetazolamide--a pilot study. Clinical neurology and neurosurgery 20040901
The phosphodiesterase III inhibitor olprinone decreases sensitivity of rat Kupffer cells to endotoxin. Alcoholism, clinical and experimental research 20040801
[Successful management of a patient for cardiac surgery with difficulty in weaning from cardiopulmonary bypass by using both isosorbide dinitrate and olprinone hydrochloride]. Masui. The Japanese journal of anesthesiology 20040701
Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery. Osaka city medical journal 20040601
Olprinone improves diaphragmatic contractility and fatigability during abdominal sepsis in a rat model. Acta anaesthesiologica Scandinavica 20040501
[Application of a PDE III inhibitor, olprinone, for fast track pediatric cardiac surgery]. Masui. The Japanese journal of anesthesiology 20040301
[Effects of olprinone hydrochloride after coronary artery bypass grafting]. Masui. The Japanese journal of anesthesiology 20040201
[Successful anesthetic management of patients with poor ventricular function using the phosphodiesterase III inhibitor, olprinone, during major cardiovascular procedures]. Masui. The Japanese journal of anesthesiology 20040201
Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry. Journal of anesthesia 20040101
Olprinone for the treatment, but not prevention, of fatigue-induced changes in guinea-pig diaphragmatic contractility. Anesthesia and analgesia 20030601
Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits. Anesthesiology 20030601
[Evaluation of the different doses of olprinone for continuous infusion after cardiopulmonary bypass for coronary artery bypass surgery]. Masui. The Japanese journal of anesthesiology 20030601
Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Molecular and cellular biochemistry 20030601
Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. British journal of clinical pharmacology 20030401
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits. Canadian journal of anaesthesia = Journal canadien d'anesthesie 20030201
Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure. Cerebrovascular diseases (Basel, Switzerland) 20030101
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. Thrombosis research 20030101
Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1. Lymphology 20021201
[Effects of olprinone hydrochloride on intraocular pressure and ocular blood flow in patients after cardiac surgery under cardiopulmonary bypass]. Masui. The Japanese journal of anesthesiology 20021101
Inhaled olprinone improves contractility of fatigued canine diaphragm. British journal of anaesthesia 20020301
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure. Acta cardiologica 20020201
Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovascular drug reviews 20020101
Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation. The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 20011001
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 20010807
A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs. Anesthesia and analgesia 20010701
Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass. Acta anaesthesiologica Scandinavica 20010401
Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient. Acta anaesthesiologica Scandinavica 20010401
Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients. Journal of cardiovascular pharmacology 20010401
The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia. Anesthesia and analgesia 20010301
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. American heart journal 19970301
[Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 19920601
Properties